塞德斯医疗公布2026年研发规划，股价近期震荡下行

Group 1 - The core focus of the company is on the development of Barzol for chronic spontaneous urticaria (CSU), with Phase III clinical trials expected to complete patient enrollment by July 2026 [1] - The company plans to announce Phase II data for nodular prurigo and atopic dermatitis in 2026, and advance the validation study of the bispecific platform CDX622 for severe asthma [1] Group 2 - The stock price has shown a downward trend over the past week, with a cumulative decline of 3.20% and a volatility of 11.49% [2] - On February 9, the stock rose by 4.42% to $24.81, but subsequently fell by 4.19% on February 12 and continued to decline by 2.42% to $23.00 on February 13, with trading volume increasing to $27.31 million on February 13 [2] - The biotechnology sector increased by 1.32% during the same period, but the company's performance diverged from the sector, while the Nasdaq index decreased by 0.22% [2] Group 3 - In February 2026, 15 institutions provided ratings, with 80% giving buy or hold ratings, and the average target price set at $54.54, indicating significant upside potential compared to the current price [3] - The company is still in a research investment phase, with an expected earnings per share of -$1.009 for Q4 2025, but long-term focus remains on the clinical progress of Barzol and other pipeline candidates [3]